Metaproterenol
Metaproterenol (metaproterenol) is a small molecule pharmaceutical. Metaproterenol was first approved as Alupent on 1982-01-01. It is used to treat asthma, bronchial spasm, chronic bronchitis, and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Metaproterenol (discontinued: Alupent, Metaproterenol, Prometa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metaproterenol sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALUPENT | Boehringer Ingelheim | N-015874 DISCN | 1982-01-01 | 2 products |
| ALUPENT | Boehringer Ingelheim | N-016402 DISCN | 1982-01-01 | 1 products |
| ALUPENT | Boehringer Ingelheim | N-017571 DISCN | 1982-01-01 | 1 products |
| ALUPENT | Boehringer Ingelheim | N-017659 DISCN | 1982-01-01 | 1 products |
| ALUPENT | Boehringer Ingelheim | N-018761 DISCN | 1983-06-30 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| prenatryl | unapproved drug other | 2021-02-19 |
| prenatryl prometa | unapproved drug other | 2024-10-08 |
| prometa | unapproved drug other | 2021-02-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| chronic bronchitis | — | D029481 | J42 |
| asthma | EFO_0000270 | D001249 | J45 |
| pulmonary emphysema | — | D011656 | J43 |
| bronchial spasm | — | D001986 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AB: Non-selective beta-adrenoreceptor agonist inhalants
— R03AB03: Orciprenaline
— R03C: Adrenergics for systemic use
— R03CB: Non-selective beta-adrenoreceptor agonists for systemic use
— R03CB03: Orciprenaline
— R03CB53: Orciprenaline, combinations
HCPCS
Code | Description |
|---|---|
| J7667 | Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligrams |
| J7668 | Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 10 milligrams |
| J7669 | Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligrams |
| J7670 | Metaproterenol sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligrams |
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metaproterenol |
| INN | orciprenaline |
| Description | Metaproterenol is a member of phenylethanolamines. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)c1cc(O)cc(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 586-06-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL776 |
| ChEBI ID | 6792 |
| PubChem CID | 4086 |
| DrugBank | DB00816 |
| UNII ID | 53QOG569E0 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Metaproterenol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,156 documents
View more details
Safety
Black-box Warning
Black-box warning for: Prenatryl, Prenatryl prometa, Prometa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
48 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use